Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: Insights from BOLERO-2

Annals of Oncology

Volumn 25, Issue 4, 2014, Pages 808-815

  Rugo, H S ^a   Pritchard, K I ^b   Gnant, M ^c   Noguchi, S ^d   Piccart, M ^e   Hortobagyi, G ^f   Baselga, J ^g   Perez, A ^h   Geberth, M ⁱ   Csoszi, T ^j   Chouinard, E ^k   Srimuninnimit, V ^l   Puttawibul, P ^m   Eakle, J ⁿ   Feng, W ^o   Bauly, H ^p   El hashimy, M ^o   Taran, T ^o   Burris, H A ^q  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d OSAKA UNIVERSITY   (Japan)

^e JULES BORDET INSTITUTE   (Belgium)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h Memorial Cancer Institute   (United States)

ⁱ Schwerpunktpraxis für Gynaekologische Onkologie   (Germany)

^j Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ^*  (Hungary)

^k Cambridge Memorial Hospital   (Canada)

^l MAHIDOL UNIVERSITY   (Thailand)

^m PRINCE OF SONGKLA UNIVERSITY   (Thailand)

ⁿ Florida Cancer Specialists   (United States)

^o NOVARTIS PHARMA AG   (Switzerland)

^p Novartis Institutes of BioMedical Research   (Sweden)

^q SARAH CANNON RESEARCH INSTITUTE   (United States)

more..

Author keywords

Advanced breast cancer; Everolimus; Mammalian target of rapamycin (mTOR); Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; EVEROLIMUS; EXEMESTANE; HORMONE RECEPTOR; PLACEBO; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LUNG INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CANCER STAGING; CLASSIFICATION; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; PATHOLOGY; POSTMENOPAUSE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84897102034     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu009     Document Type: Article

References (19)

1. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer, Version 2.2013. www.nccn.com (5 July 2013, date last accessed).
2. Cardoso F, Costa A, Norton L et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21:242-252.
3. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormonereceptor- positive advanced breast cancer. N Engl J Med 2012;366:520-529.
4. Miller TW, Hennessy BT, Gonzalez-Angulo AM et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010;120:2406-2413.
5. Beeram M, Tan QT, Tekmal RR et al. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007;18:1323-1328.
6. Boulay A, Rudloff J, Ye J et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005;11:5319-5328.
7. Afinitor® (everolimus) tablets [package insert]. East Hanover, NJ: Novartis, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf (5 July 2013, date last accessed).
8. Afinitor® (everolimus) tablets [summary of product characteristics]. Horsham, UK: Novartis Europharm Limited, 2012; http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Product_Information/human/001038/WC500022814.pdf (5 July 2013, date last accessed).
9. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116:4256-4265.
10. Yao JC, Phan AT, Chang DZ et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311-4318.
11. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
12. Beck JT, Rugo HS, Burris HA et al. BOLERO-2: health-related quality-oflife in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane. In The ASCO Annual Meeting (Poster 539), Chicago, IL, 2012.
13. Piccart M, Noguchi S, Pritchard KI et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial. In The ASCO Annual Meeting (Poster 559), Chicago, IL, 2012.
14. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v3.0 (CTCAE), 2006. http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/docs/ctcaev3.pdf (5 July 2013, date last accessed).
15. Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27: 2630-2637.
16. Bachelot T, Bourgier C, Cropet C et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30: 2718-2724.
17. Noguchi S, Masuda N, Iwata H et al. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormonereceptor- positive breast cancer in BOLERO-2. Breast Cancer 2013 (Epub ahead of print). doi:10.1007/s12282-013-0444-8.
18. Tsukamoto T, Shinohara N, Tsuchiya N et al. Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol 2011;41:17-24.
19. Wolff AC, Lazar AA, Bondarenko I et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013;31:195-202.